Macrocytic anemia overview: Difference between revisions

Jump to navigation Jump to search
 
(14 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
{{Macrocytic anemia}}
{{Macrocytic anemia}}
{{CMG}}
{{CMG}}{{AE}}{{OK}}
 
==Overview==
==Overview==
'''Macrocytosis''' is the enlargement of [[red blood cell]]s with near-constant [[haemoglobin]] concentration, and is defined by a [[mean corpuscular volume]] (MCV) of greater than 100 femtolitres (the precise criterion varies between laboratories). '''Megaloblastic anemia''' is an [[anemia]] (of [[macrocytic anaemia|macrocytic]] classification) which results from inhibition of DNA synthesis in red blood cell production. It is often due to deficiency of [[vitamin B12]] and/or [[folic acid]]. It can be the result of a lack of [[intrinsic factor]] (which lack interferes with B12 absorption), causing [[pernicious anemia]], or with other antimetabolites which poison DNA production, such as chemotherapeutic agents. It is characterized by many large immature and dysfunctional red blood cells ([[megaloblasts]]) in the bone marrow, and also by hypersegmented or multisegmented [[neutrophil]]s. <ref>Babior BM, Bunn HF, Megaloblastic Anemias. Harrison’s Principles of Internal Medicine. 13th Ed. 1994: 1726-1732. ISBN 0070323704</ref> <ref>Toh BH, van Driel IR, Gleeson PA. Mechanisms of Disease: Pernicious Anemia. NEJM 1997;337:1441.</ref>
The word "hematology," which appears to have been first used in this country in 1811, is older than might be expected, for in 1743, Thomas Schwencke (1694-1768) wrote Hamatologia, sive Sanguinis Historia, Experimentis passim superstructa etc. Hagae Comitum. Hematology, like bacteriology, has developed as the result of laboratory methods and the applications of physics and chemistry. [[Macrocytic anemia]] are the [[anemia]] which has MCV>100fL. [[Macrocytic anemia]] may be classified into 2 subtypes/groups: [[Megaloblastic anemia]] and non megaloblastic anemia. [[Folate]] is important in the production of various building blocks necessary for the production of biologic [[macromolecules]]. By combining with [[carbon]] moieties, [[tetrahydrofolate]] (THF) becomes methelenetetrahydofolate. This molecule is then able to donate carbon moieties to form purines, dTMP, and methionine. Of note, [[Vitamin B12]] is also a [[cofactor]] in the production of [[methionine]]. THF is the resulting molecule after donation of carbon moieties except in the synthesis of dTMP from dUMP. DHF (dihydrofolate) results from this reaction. DHF reductase must act on DHF to participate in reactions again. In 60% of anemic patients, [[megaloblastic anemia]] affects 2-4% of population. Patients of all age groups may develop [[megaloblastic anemia]]. The incidence of [[megaloblastic anemia]] increases with age. [[Megaloblastic anemia]] commonly affects older age group. Males are more commonly affected by [[megaloblastic anemia]] than females. In deficiencies of [[Vitamin B12|vitamin b12]] and [[folate]] causing [[megaloblastic anemia]], supplementation are made with [[Cyanocobalamine]] and [[Folic Acid]] respectively based on the severity and the cause. [[LDH]] falls in 2 days. [[Hypokalemia]] requiring replacement can occur in the acute phase as new cells are being generated rapidly. A [[reticulocytosis]] begins in 3-5 days and peaks in 10 days. The [[Hematocrit]] will rise within 10days. If it does not, suspect another disorder. Hypersegmented [[polymorphonuclear cells]] disappear in 10-14 days.
 
== Historical Perspective ==
[[Megaloblastic anemia]] and [[pernicious anemia]] was first discovered by Osler and Gardner in 1877 at Montreal. Increase in [[bone marrow cells]] was noted by Cohnheim in 1876.
 
==Classification==
[[Macrocytic anemia]] are the [[anemia]] which has MCV>100fL. [[Macrocytic anemia]] may be classified into 2 subtypes/groups: [[Megaloblastic anemia]] and non megaloblastic anemia.
 
==Pathophysiology==
[[Folate]] is important in the production of various building blocks necessary for the production of biologic [[macromolecules]]. By combining with [[carbon]] moieties, [[tetrahydrofolate]] (THF) becomes methelenetetrahydofolate. This molecule is then able to donate carbon moieties to form purines, dTMP, and methionine. Of note, [[Vitamin B12]] is also a [[cofactor]] in the production of [[methionine]]. THF is the resulting molecule after donation of carbon moieties except in the synthesis of dTMP from dUMP. DHF (dihydrofolate) results from this reaction. DHF reductase must act on DHF to participate in reactions again. The two metabolically active forms of [[Vitamin B12]] are Methycobalamin and [[Adenosylcobalamin]]. The former is important in methionine synthesis. Methionine is necessary for the production of [[choline]][[phospholipids]]. Adenosylcobalamin is necessary to convert methylmalonyl CoA to [[succinyl-CoA]]. Interruption of this reaction eventually leads to nonphysiologic fatty acid production and abnormal neuronal lipid production. B12 deficiency also leads to folate metabolism derangement. Tissue folate levels are reduced in the setting of Vitamin B12 deficiency through a complicated biochemical pathway. This is known as the “folate trap hypothesis” and explains why large doses of folate will help the hematological manifestations. The mechanism of the neurologic manifestations remains independent of folate metabolism.
==Causes==
The common causes of [[megaloblastic anemia]] are less dietray intake, autoimmune disorders like [[pernicious anemia]], [[alcoholism]], increased demands like in [[pregnancy]] and due to drugs.
 
==Differentiating from Other Diseases==
The most important differential is whether the patient has ACD alone or ACD with ongoing [[iron deficiency anemia]] (ACD/IDA). The following parameters will distinguish the two: Soluble [[transferrin receptor]] levels (sTfR) and/or the sTfR-[[ferritin]] index sTfR and the sTfR-[[ferritin]] index are normal in uncomplicated ACD, while both are elevated when IDA is also. Percentage of [[hypochromic]] [[red cells]] and [[reticulocyte]] [[hemoglobin]] may help.
 
==Epidemiology and Demographics==
In 60% of anemic patients, [[megaloblastic anemia]] affects 2-4% of population. Patients of all age groups may develop [[megaloblastic anemia]]. The incidence of [[megaloblastic anemia]] increases with age. [[Megaloblastic anemia]] commonly affects older age group. Males are more commonly affected by [[megaloblastic anemia]] than females.
 
==Risk Factors==
Common risk factors of [[megaloblastic anemia]] include nutritional factors like [[alcoholism]], [[elderly]], [[Pregnancy|pregnant]], vegans, and malabsorptive syndromes
 
==Screening==
There is insufficient evidence to recommend routine screening for [[megaloblastic anemia]]
 
==Natural History, Complications, and Prognosis==
The symptoms of [[megaloblastic anemia]] typically develop many years after defieciency of [[Vitamin B12]]. If left untreated, patients with [[megaloblastic anemia]] may progress to develop [[Subacute combined degeneration of spinal cord]], [[Peripheral neuropathy]], and [[Dementia]].
 
== Diagnosis ==
 
===Diagnostic Study of Choice===
[[Homocysteine]] and [[methylmalonic acid]] levels can be helpful in confirmation. Both serum [[homocysteine]] and [[methylmalonic acid]] (MMA) levels are increased in helpful confirmatory tests for [[cobalamin]] and [[folate]] deficiencies. [[Homocysteine]] but not [[methylmalonic acid]] is increased in [[folate]] deficiency.
 
===History and Symptoms===
History may include higher [[MCV]] specially in [[neonates]] and [[infants]], [[alcohol]] use, [[medications]] (eg, [[anticonvulsants]], [[zidovudine]], [[immunosuppressive]] agents), [[congenital heart disease]], [[Down syndrome]], [[reticulocytosis]], [[bone marrow failure]]/[[dysplasia]], [[liver disease]], [[thyroid disease]], [[hemolytic anemias]] with [[reticulocytosis]] and [[myelodysplastic syndromes]] (MDS). [[Macrocytosis]] is a common feature of [[MDS]], especially in older adults. Patients with [[B12 deficiency]] show neurologic dysfunction, [[anemia]] symptoms such as [[fatigue]], [[dyspnea]], [[lightheadedness]], and [[anorexia]], [[high output cardiac failure]], [[angina]], [[diarrhea]], [[cheilosis]], [[glossitis]], [[Subacute combined degeneration of spinal cord|subacute combined degeneration]], broad based [[gait]], [[ataxia]], [[numbness]] or [[paresthesias]], Rhomberg and Babinski’s sign. [[Dementia]] may progress to frank “Megaloblastic Madness”
 
===Physical Examination===
Common physical examination findings of [[megaloblastic anemia]] include [[glossitis]], [[pallor]], [[mouth ulcers]], [[vitiligo]], [[Subacute combined degeneration of spinal cord|subacute combined degeneration]], and positive [[Romberg's test|Romberg's]] sign.
 
===Laboratory Findings===
The lab findings include measuring levels of [[Vitamin B12|vitamin b12]], [[folate]], [[methylmalonic acid]], and [[homocysteine]].
 
===Electrocardiogram===
There are no [[echocardiogram]]/[[ultrasound]] findings associated with [[megaloblastic anemia]]. However, an [[echocardiogram]] may be helpful in the diagnosis of complications of [[megaloblastic anemia]] which include features of [[myocardial infarction]] when associated with [[hyperhomocysteinemia]] and [[dilated cardiomyopathy]], and an [[ultrasound]] may show complication like [[splenomegaly]].
 
===X-ray===
There are no x-ray findings associated with [[megaloblastic anemia]]
 
===Echocardiography and Ultrasound===
There are no [[echocardiogram]]/[[ultrasound]] findings associated with [[megaloblastic anemia]]. However, an [[echocardiogram]] may be helpful in the diagnosis of complications of [[megaloblastic anemia]] which include features of [[myocardial infarction]] when associated with [[hyperhomocysteinemia]] and [[dilated cardiomyopathy]], and an [[ultrasound]] may show complication like [[splenomegaly]].
 
===CT scan===
There are no [[CT scan]] findings associated with [[megaloblastic anemia]].
 
===MRI===
There are no [[MRI]] findings associated with [[megaloblastic anemia]]. However, an [[MRI]] may be helpful in the diagnosis of complications of [[megaloblastic anemia]], which include [[Subacute combined degeneration of spinal cord|subacute combined degeneration]]
 
===Other Imaging Findings===
There are no other imaging findings associated with [[megaloblastic anemia]]
 
===Other Diagnostic Studies===
There are no other diagnostic findings associated with [[megaloblastic anemia]]
 
==Treatment==
===Medical Therapy===
In deficiencies of [[Vitamin B12|vitamin b12]] and [[folate]] causing [[megaloblastic anemia]], supplementation are made with [[Cyanocobalamine]] and [[Folic Acid]] respectively based on the severity and the cause. [[LDH]] falls in 2 days. [[Hypokalemia]] requiring replacement can occur in the acute phase as new cells are being generated rapidly. A [[reticulocytosis]] begins in 3-5 days and peaks in 10 days. The [[Hematocrit]] will rise within 10days. If it does not, suspect another disorder. Hypersegmented [[polymorphonuclear cells]] disappear in 10-14 days.
 
=== Interventions ===
 
===Surgery===
Surgical intervention is not recommended for the management of [[megaloblastic anemia]]
 
===Primary Prevention===
Green leafy vegetables and meat are a good source of [[Vitamin B12|Vitamin B-12]]. [[Alcohol]] consumption can lead to [[macrocytic anemia]]. These are some of the primary ways to reduce the incidence of [[macrocytic anemia]].
 
===Secondary Prevention===
[[Folic Acid|Folic acid]] supplementation in conditions which need more [[folate]] like pregnancy and lactation or in [[malabsorption]] e.g., [[celiac disease]] or a loss e.g., chronic hemolytic disorder. [[Folic Acid|Folic acid]] supplementation in pregnant women can also prevent fetal [[neural tube defects]].
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[es:Anemia megaloblástica]]
[[gl:Anemia megaloblástica]]
[[he:אנמיה מגלובלסטית]]
[[it:Anemia megaloblastica]]
[[pl:Niedokrwistość megaloblastyczna]]
[[pt:Anemia megaloblástica]]
[[ru:Пернициозная анемия]]
[[sl:Megaloblastna anemija]]
[[sr:Мегалобластна анемија]]
[[tr:Megaloblastik anemi]]
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 20:56, 6 November 2018

Macrocytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Macrocytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Macrocytic anemia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Macrocytic anemia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Macrocytic anemia overview

CDC on Macrocytic anemia overview

Macrocytic anemia overview in the news

Blogs on Macrocytic anemia overview

Directions to Hospitals Treating Macrocytic anemia

Risk calculators and risk factors for Macrocytic anemia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]

Overview

The word "hematology," which appears to have been first used in this country in 1811, is older than might be expected, for in 1743, Thomas Schwencke (1694-1768) wrote Hamatologia, sive Sanguinis Historia, Experimentis passim superstructa etc. Hagae Comitum. Hematology, like bacteriology, has developed as the result of laboratory methods and the applications of physics and chemistry. Macrocytic anemia are the anemia which has MCV>100fL. Macrocytic anemia may be classified into 2 subtypes/groups: Megaloblastic anemia and non megaloblastic anemia. Folate is important in the production of various building blocks necessary for the production of biologic macromolecules. By combining with carbon moieties, tetrahydrofolate (THF) becomes methelenetetrahydofolate. This molecule is then able to donate carbon moieties to form purines, dTMP, and methionine. Of note, Vitamin B12 is also a cofactor in the production of methionine. THF is the resulting molecule after donation of carbon moieties except in the synthesis of dTMP from dUMP. DHF (dihydrofolate) results from this reaction. DHF reductase must act on DHF to participate in reactions again. In 60% of anemic patients, megaloblastic anemia affects 2-4% of population. Patients of all age groups may develop megaloblastic anemia. The incidence of megaloblastic anemia increases with age. Megaloblastic anemia commonly affects older age group. Males are more commonly affected by megaloblastic anemia than females. In deficiencies of vitamin b12 and folate causing megaloblastic anemia, supplementation are made with Cyanocobalamine and Folic Acid respectively based on the severity and the cause. LDH falls in 2 days. Hypokalemia requiring replacement can occur in the acute phase as new cells are being generated rapidly. A reticulocytosis begins in 3-5 days and peaks in 10 days. The Hematocrit will rise within 10days. If it does not, suspect another disorder. Hypersegmented polymorphonuclear cells disappear in 10-14 days.

Historical Perspective

Megaloblastic anemia and pernicious anemia was first discovered by Osler and Gardner in 1877 at Montreal. Increase in bone marrow cells was noted by Cohnheim in 1876.

Classification

Macrocytic anemia are the anemia which has MCV>100fL. Macrocytic anemia may be classified into 2 subtypes/groups: Megaloblastic anemia and non megaloblastic anemia.

Pathophysiology

Folate is important in the production of various building blocks necessary for the production of biologic macromolecules. By combining with carbon moieties, tetrahydrofolate (THF) becomes methelenetetrahydofolate. This molecule is then able to donate carbon moieties to form purines, dTMP, and methionine. Of note, Vitamin B12 is also a cofactor in the production of methionine. THF is the resulting molecule after donation of carbon moieties except in the synthesis of dTMP from dUMP. DHF (dihydrofolate) results from this reaction. DHF reductase must act on DHF to participate in reactions again. The two metabolically active forms of Vitamin B12 are Methycobalamin and Adenosylcobalamin. The former is important in methionine synthesis. Methionine is necessary for the production of cholinephospholipids. Adenosylcobalamin is necessary to convert methylmalonyl CoA to succinyl-CoA. Interruption of this reaction eventually leads to nonphysiologic fatty acid production and abnormal neuronal lipid production. B12 deficiency also leads to folate metabolism derangement. Tissue folate levels are reduced in the setting of Vitamin B12 deficiency through a complicated biochemical pathway. This is known as the “folate trap hypothesis” and explains why large doses of folate will help the hematological manifestations. The mechanism of the neurologic manifestations remains independent of folate metabolism.

Causes

The common causes of megaloblastic anemia are less dietray intake, autoimmune disorders like pernicious anemia, alcoholism, increased demands like in pregnancy and due to drugs.

Differentiating from Other Diseases

The most important differential is whether the patient has ACD alone or ACD with ongoing iron deficiency anemia (ACD/IDA). The following parameters will distinguish the two: Soluble transferrin receptor levels (sTfR) and/or the sTfR-ferritin index sTfR and the sTfR-ferritin index are normal in uncomplicated ACD, while both are elevated when IDA is also. Percentage of hypochromic red cells and reticulocyte hemoglobin may help.

Epidemiology and Demographics

In 60% of anemic patients, megaloblastic anemia affects 2-4% of population. Patients of all age groups may develop megaloblastic anemia. The incidence of megaloblastic anemia increases with age. Megaloblastic anemia commonly affects older age group. Males are more commonly affected by megaloblastic anemia than females.

Risk Factors

Common risk factors of megaloblastic anemia include nutritional factors like alcoholism, elderly, pregnant, vegans, and malabsorptive syndromes

Screening

There is insufficient evidence to recommend routine screening for megaloblastic anemia

Natural History, Complications, and Prognosis

The symptoms of megaloblastic anemia typically develop many years after defieciency of Vitamin B12. If left untreated, patients with megaloblastic anemia may progress to develop Subacute combined degeneration of spinal cord, Peripheral neuropathy, and Dementia.

Diagnosis

Diagnostic Study of Choice

Homocysteine and methylmalonic acid levels can be helpful in confirmation. Both serum homocysteine and methylmalonic acid (MMA) levels are increased in helpful confirmatory tests for cobalamin and folate deficiencies. Homocysteine but not methylmalonic acid is increased in folate deficiency.

History and Symptoms

History may include higher MCV specially in neonates and infants, alcohol use, medications (eg, anticonvulsants, zidovudine, immunosuppressive agents), congenital heart disease, Down syndrome, reticulocytosis, bone marrow failure/dysplasia, liver disease, thyroid disease, hemolytic anemias with reticulocytosis and myelodysplastic syndromes (MDS). Macrocytosis is a common feature of MDS, especially in older adults. Patients with B12 deficiency show neurologic dysfunction, anemia symptoms such as fatigue, dyspnea, lightheadedness, and anorexia, high output cardiac failure, angina, diarrhea, cheilosis, glossitis, subacute combined degeneration, broad based gait, ataxia, numbness or paresthesias, Rhomberg and Babinski’s sign. Dementia may progress to frank “Megaloblastic Madness”

Physical Examination

Common physical examination findings of megaloblastic anemia include glossitis, pallor, mouth ulcers, vitiligo, subacute combined degeneration, and positive Romberg's sign.

Laboratory Findings

The lab findings include measuring levels of vitamin b12, folate, methylmalonic acid, and homocysteine.

Electrocardiogram

There are no echocardiogram/ultrasound findings associated with megaloblastic anemia. However, an echocardiogram may be helpful in the diagnosis of complications of megaloblastic anemia which include features of myocardial infarction when associated with hyperhomocysteinemia and dilated cardiomyopathy, and an ultrasound may show complication like splenomegaly.

X-ray

There are no x-ray findings associated with megaloblastic anemia

Echocardiography and Ultrasound

There are no echocardiogram/ultrasound findings associated with megaloblastic anemia. However, an echocardiogram may be helpful in the diagnosis of complications of megaloblastic anemia which include features of myocardial infarction when associated with hyperhomocysteinemia and dilated cardiomyopathy, and an ultrasound may show complication like splenomegaly.

CT scan

There are no CT scan findings associated with megaloblastic anemia.

MRI

There are no MRI findings associated with megaloblastic anemia. However, an MRI may be helpful in the diagnosis of complications of megaloblastic anemia, which include subacute combined degeneration

Other Imaging Findings

There are no other imaging findings associated with megaloblastic anemia

Other Diagnostic Studies

There are no other diagnostic findings associated with megaloblastic anemia

Treatment

Medical Therapy

In deficiencies of vitamin b12 and folate causing megaloblastic anemia, supplementation are made with Cyanocobalamine and Folic Acid respectively based on the severity and the cause. LDH falls in 2 days. Hypokalemia requiring replacement can occur in the acute phase as new cells are being generated rapidly. A reticulocytosis begins in 3-5 days and peaks in 10 days. The Hematocrit will rise within 10days. If it does not, suspect another disorder. Hypersegmented polymorphonuclear cells disappear in 10-14 days.

Interventions

Surgery

Surgical intervention is not recommended for the management of megaloblastic anemia

Primary Prevention

Green leafy vegetables and meat are a good source of Vitamin B-12. Alcohol consumption can lead to macrocytic anemia. These are some of the primary ways to reduce the incidence of macrocytic anemia.

Secondary Prevention

Folic acid supplementation in conditions which need more folate like pregnancy and lactation or in malabsorption e.g., celiac disease or a loss e.g., chronic hemolytic disorder. Folic acid supplementation in pregnant women can also prevent fetal neural tube defects.

References

Template:WikiDoc Sources